+关注
Babaluke
暂无个人介绍
IP属地：未知
0
关注
0
粉丝
0
主题
0
勋章
主贴
热门
Babaluke
2021-06-23
Great ariticle, would you like to share it?
@小虎活动:【老虎7周年】集卡瓜分百万奖金
Babaluke
2021-06-23
Ok
抱歉，原内容已删除
Babaluke
2021-06-23
Ok
抱歉，原内容已删除
Babaluke
2021-06-23
What
抱歉，原内容已删除
Babaluke
2021-06-23
Yums
抱歉，原内容已删除
Babaluke
2021-06-23
Ok
抱歉，原内容已删除
Babaluke
2021-06-23
Cool
抱歉，原内容已删除
Babaluke
2021-06-23
Good
GSAT Stock: Why One Analyst Sees 150%+ Upside for Globalstar
Babaluke
2021-06-23
Good
抱歉，原内容已删除
去老虎APP查看更多动态
{"i18n":{"language":"zh_CN"},"userPageInfo":{"id":"3584774162933077","uuid":"3584774162933077","gmtCreate":1621680138843,"gmtModify":1624441399370,"name":"Babaluke","pinyin":"babaluke","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.tigerbbs.com/cf1bdc263bcb63f2412eb36286eaedda","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":0,"headSize":0,"tweetSize":9,"questionSize":0,"limitLevel":999,"accountStatus":3,"level":{"id":0,"name":"","nameTw":"","represent":"","factor":"","iconColor":"","bgColor":""},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-1","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"出道虎友","description":"加入老虎社区500天","bigImgUrl":"https://static.tigerbbs.com/0e4d0ca1da0456dc7894c946d44bf9ab","smallImgUrl":"https://static.tigerbbs.com/0f2f65e8ce4cfaae8db2bea9b127f58b","grayImgUrl":"https://static.tigerbbs.com/c5948a31b6edf154422335b265235809","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.10.05","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001}],"userBadgeCount":1,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":1,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":123566429,"gmtCreate":1624429967061,"gmtModify":1634006224487,"author":{"id":"3584774162933077","authorId":"3584774162933077","name":"Babaluke","avatar":"https://static.tigerbbs.com/cf1bdc263bcb63f2412eb36286eaedda","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3584774162933077","authorIdStr":"3584774162933077"},"themes":[],"htmlText":"Great ariticle, would you like to share it?","listText":"Great ariticle, would you like to share it?","text":"Great ariticle, would you like to share it?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/123566429","repostId":"114899451","repostType":1,"repost":{"id":114899451,"gmtCreate":1623063308869,"gmtModify":1631884627596,"author":{"id":"36984908995200","authorId":"36984908995200","name":"小虎活动","avatar":"https://static.tigerbbs.com/9e396d03155923b283948d2dec9191f8","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"36984908995200","authorIdStr":"36984908995200"},"themes":[],"title":"【老虎7周年】集卡瓜分百万奖金","htmlText":"老虎7周年给大家发福利了，集齐TIGER五个字母即有机会瓜分百万奖金，你准备好了吗？ <a href=\"https://www.itiger.com/activity/market/2021/7th-anniversary?lang=zh_CN\" target=\"_blank\">戳我即可参与活动</a> 如何参与？ 用户可通过完成活动页面展示的当日任务列表来获得字母卡，每完成一个任务即可随机获得一个字母，用户集齐“TIGER”五个字母即可参与瓜分百万股票代金券，每个用户单日最多可获得20张字母卡（不包括好友赠予和魔法卡）。 用户在活动期间邀请累计7名好友完成注册并开户（注册时间和开户时间均在活动期间），即可获得一张魔法卡（每人仅可获得一张魔法卡）。魔法卡可用于兑换TIGER中的任意一个字母。如果用户的某一字母卡数量为0，则字母卡为灰色，用户可通过点击灰色的字母卡向好友索要卡片；如果用户的字母卡数量大于0，则字母卡为彩色，用户可通过点击彩色的字母卡向好友赠送卡片。当用户集齐TIGER之后将无法再索要卡片或者赠送卡片。  如何获得奖励？ 用户可在2021年7月1日至2021年7月2日期间进行开奖，所有集齐TIGER的客户可点击活动页面的“开奖”按钮，即可查看自己瓜分到的股票代金券奖励。在开奖时间段内未点击开奖的用户将无法获得奖励。 奖励发放： 股票代金券将在开奖后的1个工作日内发放至用户的奖励中心，用户需要在奖励发放后的20天内前往【Tiger Trade APP > 我的 > 活动奖励】领取，过期未领取的奖励将自动失效。 重要提示： 本次7周年活动涉及不同国家和地区，由于各地区的监管要求不同，不同地区的活动奖励会有所区别。欲知详情，请点击下方活动链接，登陆您的账号，并点击“活动规则“查看详情。","listText":"老虎7周年给大家发福利了，集齐TIGER五个字母即有机会瓜分百万奖金，你准备好了吗？ <a href=\"https://www.itiger.com/activity/market/2021/7th-anniversary?lang=zh_CN\" target=\"_blank\">戳我即可参与活动</a> 如何参与？ 用户可通过完成活动页面展示的当日任务列表来获得字母卡，每完成一个任务即可随机获得一个字母，用户集齐“TIGER”五个字母即可参与瓜分百万股票代金券，每个用户单日最多可获得20张字母卡（不包括好友赠予和魔法卡）。 用户在活动期间邀请累计7名好友完成注册并开户（注册时间和开户时间均在活动期间），即可获得一张魔法卡（每人仅可获得一张魔法卡）。魔法卡可用于兑换TIGER中的任意一个字母。如果用户的某一字母卡数量为0，则字母卡为灰色，用户可通过点击灰色的字母卡向好友索要卡片；如果用户的字母卡数量大于0，则字母卡为彩色，用户可通过点击彩色的字母卡向好友赠送卡片。当用户集齐TIGER之后将无法再索要卡片或者赠送卡片。  如何获得奖励？ 用户可在2021年7月1日至2021年7月2日期间进行开奖，所有集齐TIGER的客户可点击活动页面的“开奖”按钮，即可查看自己瓜分到的股票代金券奖励。在开奖时间段内未点击开奖的用户将无法获得奖励。 奖励发放： 股票代金券将在开奖后的1个工作日内发放至用户的奖励中心，用户需要在奖励发放后的20天内前往【Tiger Trade APP > 我的 > 活动奖励】领取，过期未领取的奖励将自动失效。 重要提示： 本次7周年活动涉及不同国家和地区，由于各地区的监管要求不同，不同地区的活动奖励会有所区别。欲知详情，请点击下方活动链接，登陆您的账号，并点击“活动规则“查看详情。","text":"老虎7周年给大家发福利了，集齐TIGER五个字母即有机会瓜分百万奖金，你准备好了吗？ 戳我即可参与活动 \u0001如何参与？ 用户可通过完成活动页面展示的当日任务列表来获得字母卡，每完成一个任务即可随机获得一个字母，用户集齐“TIGER”五个字母即可参与瓜分百万股票代金券，每个用户单日最多可获得20张字母卡（不包括好友赠予和魔法卡）。 用户在活动期间邀请累计7名好友完成注册并开户（注册时间和开户时间均在活动期间），即可获得一张魔法卡（每人仅可获得一张魔法卡）。魔法卡可用于兑换TIGER中的任意一个字母。\u0001如果用户的某一字母卡数量为0，则字母卡为灰色，用户可通过点击灰色的字母卡向好友索要卡片；如果用户的字母卡数量大于0，则字母卡为彩色，用户可通过点击彩色的字母卡向好友赠送卡片。当用户集齐TIGER之后将无法再索要卡片或者赠送卡片。 \u0001 \u0001如何获得奖励？ 用户可在2021年7月1日至2021年7月2日期间进行开奖，所有集齐TIGER的客户可点击活动页面的“开奖”按钮，即可查看自己瓜分到的股票代金券奖励。在开奖时间段内未点击开奖的用户将无法获得奖励。\u0001 奖励发放： 股票代金券将在开奖后的1个工作日内发放至用户的奖励中心，用户需要在奖励发放后的20天内前往【Tiger Trade APP > 我的 > 活动奖励】领取，过期未领取的奖励将自动失效。 重要提示： 本次7周年活动涉及不同国家和地区，由于各地区的监管要求不同，不同地区的活动奖励会有所区别。欲知详情，请点击下方活动链接，登陆您的账号，并点击“活动规则“查看详情。","images":[{"img":"https://static.tigerbbs.com/ab28db31a19b458d604a8bf02becddd3","width":"415","height":"125"},{"img":"https://static.tigerbbs.com/5227ebb594fe55b532c840acef147d7b","width":"415","height":"495"},{"img":"https://static.tigerbbs.com/92e88357b534f504b3088bc22f577a83","width":"415","height":"326"}],"top":1,"highlighted":2,"essential":1,"paper":2,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/114899451","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":8,"langContent":"CN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":322,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":123518556,"gmtCreate":1624429005975,"gmtModify":1634006232788,"author":{"id":"3584774162933077","authorId":"3584774162933077","name":"Babaluke","avatar":"https://static.tigerbbs.com/cf1bdc263bcb63f2412eb36286eaedda","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3584774162933077","authorIdStr":"3584774162933077"},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/123518556","repostId":"2145671770","repostType":2,"isVote":1,"tweetType":1,"viewCount":485,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":123510136,"gmtCreate":1624428873625,"gmtModify":1634006234187,"author":{"id":"3584774162933077","authorId":"3584774162933077","name":"Babaluke","avatar":"https://static.tigerbbs.com/cf1bdc263bcb63f2412eb36286eaedda","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3584774162933077","authorIdStr":"3584774162933077"},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/123510136","repostId":"1123710128","repostType":4,"isVote":1,"tweetType":1,"viewCount":431,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":123597682,"gmtCreate":1624428375546,"gmtModify":1634006238087,"author":{"id":"3584774162933077","authorId":"3584774162933077","name":"Babaluke","avatar":"https://static.tigerbbs.com/cf1bdc263bcb63f2412eb36286eaedda","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3584774162933077","authorIdStr":"3584774162933077"},"themes":[],"htmlText":"What","listText":"What","text":"What","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/123597682","repostId":"1123710128","repostType":4,"isVote":1,"tweetType":1,"viewCount":313,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":123597355,"gmtCreate":1624428362077,"gmtModify":1634006238208,"author":{"id":"3584774162933077","authorId":"3584774162933077","name":"Babaluke","avatar":"https://static.tigerbbs.com/cf1bdc263bcb63f2412eb36286eaedda","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3584774162933077","authorIdStr":"3584774162933077"},"themes":[],"htmlText":"Yums","listText":"Yums","text":"Yums","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/123597355","repostId":"1126010678","repostType":4,"isVote":1,"tweetType":1,"viewCount":353,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":123594843,"gmtCreate":1624428337982,"gmtModify":1634006238572,"author":{"id":"3584774162933077","authorId":"3584774162933077","name":"Babaluke","avatar":"https://static.tigerbbs.com/cf1bdc263bcb63f2412eb36286eaedda","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3584774162933077","authorIdStr":"3584774162933077"},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/123594843","repostId":"2145057786","repostType":4,"isVote":1,"tweetType":1,"viewCount":296,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":123595713,"gmtCreate":1624428311132,"gmtModify":1634006238814,"author":{"id":"3584774162933077","authorId":"3584774162933077","name":"Babaluke","avatar":"https://static.tigerbbs.com/cf1bdc263bcb63f2412eb36286eaedda","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3584774162933077","authorIdStr":"3584774162933077"},"themes":[],"htmlText":"Cool","listText":"Cool","text":"Cool","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/123595713","repostId":"2145066250","repostType":4,"isVote":1,"tweetType":1,"viewCount":323,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":123592750,"gmtCreate":1624428287070,"gmtModify":1634006239664,"author":{"id":"3584774162933077","authorId":"3584774162933077","name":"Babaluke","avatar":"https://static.tigerbbs.com/cf1bdc263bcb63f2412eb36286eaedda","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3584774162933077","authorIdStr":"3584774162933077"},"themes":[],"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/123592750","repostId":"1192380860","repostType":4,"repost":{"id":"1192380860","kind":"news","pubTimestamp":1624418912,"share":"https://www.laohu8.com/m/news/1192380860?lang=&edition=full","pubTime":"2021-06-23 11:28","market":"us","language":"en","title":"GSAT Stock: Why One Analyst Sees 150%+ Upside for Globalstar","url":"https://stock-news.laohu8.com/highlight/detail?id=1192380860","media":"investorplace","summary":"Globalstar(NYSEAMERICAN:GSAT) shares are rising higher on Monday after an analyst initiated coverage","content":"<p><b>Globalstar</b>(NYSEAMERICAN:<b><u>GSAT</u></b>) shares are rising higher on Monday after an analyst initiated coverage of the stock with an incredibly bullish stance.</p>\n<p>B. Riley analyst Mike Crawford is behind the positive movement for GSAT stock today. He started off coverage of the stock witha buy rating. That has him opposite of the only other analyst covering the stockwith their sell rating. This means the consensus rating for the stock is hold.</p>\n<p>In addition to that bullish buy rating, Crawford also includes a price target of $3.25 per share for GSAT stock. That is well above the consensus price target of 55 cents per share for the stock. It’s also a massive 152% upside for the stock over its closing price of $1.29 per share when markets closed on Friday.</p>\n<p>So what has this B. Riley analyst taking such a bullish stance on GSAT stock. It all has to do with the company’s future potential.</p>\n<p>According to Crawford, Globalstar is finally getting to a point where it will start reporting returns. He believes that this makes it a great time to jump into the stock before the market figures this out, reports<i>TheFly.com</i>.</p>\n<p>Investors seem to agree as GSAT is seeing heavy trading today. As of this writing, more than 114 million shares of the stock have changed hands. That’s a massive jump over its daily average trading volume of about 19.3 million shares.</p>\n<p>GSAT stock was up 19.8% as of Monday afternoon and is up 352.9% since the start of the year.</p>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>GSAT Stock: Why One Analyst Sees 150%+ Upside for Globalstar</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGSAT Stock: Why One Analyst Sees 150%+ Upside for Globalstar\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-23 11:28 GMT+8 <a href=https://investorplace.com/2021/06/gsat-stock-why-one-analyst-sees-150-upside-for-globalstar/><strong>investorplace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Globalstar(NYSEAMERICAN:GSAT) shares are rising higher on Monday after an analyst initiated coverage of the stock with an incredibly bullish stance.\nB. Riley analyst Mike Crawford is behind the ...</p>\n\n<a href=\"https://investorplace.com/2021/06/gsat-stock-why-one-analyst-sees-150-upside-for-globalstar/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"GSAT":"全球星"},"source_url":"https://investorplace.com/2021/06/gsat-stock-why-one-analyst-sees-150-upside-for-globalstar/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1192380860","content_text":"Globalstar(NYSEAMERICAN:GSAT) shares are rising higher on Monday after an analyst initiated coverage of the stock with an incredibly bullish stance.\nB. Riley analyst Mike Crawford is behind the positive movement for GSAT stock today. He started off coverage of the stock witha buy rating. That has him opposite of the only other analyst covering the stockwith their sell rating. This means the consensus rating for the stock is hold.\nIn addition to that bullish buy rating, Crawford also includes a price target of $3.25 per share for GSAT stock. That is well above the consensus price target of 55 cents per share for the stock. It’s also a massive 152% upside for the stock over its closing price of $1.29 per share when markets closed on Friday.\nSo what has this B. Riley analyst taking such a bullish stance on GSAT stock. It all has to do with the company’s future potential.\nAccording to Crawford, Globalstar is finally getting to a point where it will start reporting returns. He believes that this makes it a great time to jump into the stock before the market figures this out, reportsTheFly.com.\nInvestors seem to agree as GSAT is seeing heavy trading today. As of this writing, more than 114 million shares of the stock have changed hands. That’s a massive jump over its daily average trading volume of about 19.3 million shares.\nGSAT stock was up 19.8% as of Monday afternoon and is up 352.9% since the start of the year.","news_type":1},"isVote":1,"tweetType":1,"viewCount":433,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":123592828,"gmtCreate":1624428233064,"gmtModify":1634006240151,"author":{"id":"3584774162933077","authorId":"3584774162933077","name":"Babaluke","avatar":"https://static.tigerbbs.com/cf1bdc263bcb63f2412eb36286eaedda","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3584774162933077","authorIdStr":"3584774162933077"},"themes":[],"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/123592828","repostId":"1174011543","repostType":4,"isVote":1,"tweetType":1,"viewCount":389,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":123566429,"gmtCreate":1624429967061,"gmtModify":1634006224487,"author":{"id":"3584774162933077","authorId":"3584774162933077","name":"Babaluke","avatar":"https://static.tigerbbs.com/cf1bdc263bcb63f2412eb36286eaedda","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3584774162933077","authorIdStr":"3584774162933077"},"themes":[],"htmlText":"Great ariticle, would you like to share it?","listText":"Great ariticle, would you like to share it?","text":"Great ariticle, would you like to share it?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/123566429","repostId":"114899451","repostType":1,"repost":{"id":114899451,"gmtCreate":1623063308869,"gmtModify":1631884627596,"author":{"id":"36984908995200","authorId":"36984908995200","name":"小虎活动","avatar":"https://static.tigerbbs.com/9e396d03155923b283948d2dec9191f8","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"36984908995200","authorIdStr":"36984908995200"},"themes":[],"title":"【老虎7周年】集卡瓜分百万奖金","htmlText":"老虎7周年给大家发福利了，集齐TIGER五个字母即有机会瓜分百万奖金，你准备好了吗？ <a href=\"https://www.itiger.com/activity/market/2021/7th-anniversary?lang=zh_CN\" target=\"_blank\">戳我即可参与活动</a> 如何参与？ 用户可通过完成活动页面展示的当日任务列表来获得字母卡，每完成一个任务即可随机获得一个字母，用户集齐“TIGER”五个字母即可参与瓜分百万股票代金券，每个用户单日最多可获得20张字母卡（不包括好友赠予和魔法卡）。 用户在活动期间邀请累计7名好友完成注册并开户（注册时间和开户时间均在活动期间），即可获得一张魔法卡（每人仅可获得一张魔法卡）。魔法卡可用于兑换TIGER中的任意一个字母。如果用户的某一字母卡数量为0，则字母卡为灰色，用户可通过点击灰色的字母卡向好友索要卡片；如果用户的字母卡数量大于0，则字母卡为彩色，用户可通过点击彩色的字母卡向好友赠送卡片。当用户集齐TIGER之后将无法再索要卡片或者赠送卡片。  如何获得奖励？ 用户可在2021年7月1日至2021年7月2日期间进行开奖，所有集齐TIGER的客户可点击活动页面的“开奖”按钮，即可查看自己瓜分到的股票代金券奖励。在开奖时间段内未点击开奖的用户将无法获得奖励。 奖励发放： 股票代金券将在开奖后的1个工作日内发放至用户的奖励中心，用户需要在奖励发放后的20天内前往【Tiger Trade APP > 我的 > 活动奖励】领取，过期未领取的奖励将自动失效。 重要提示： 本次7周年活动涉及不同国家和地区，由于各地区的监管要求不同，不同地区的活动奖励会有所区别。欲知详情，请点击下方活动链接，登陆您的账号，并点击“活动规则“查看详情。","listText":"老虎7周年给大家发福利了，集齐TIGER五个字母即有机会瓜分百万奖金，你准备好了吗？ <a href=\"https://www.itiger.com/activity/market/2021/7th-anniversary?lang=zh_CN\" target=\"_blank\">戳我即可参与活动</a> 如何参与？ 用户可通过完成活动页面展示的当日任务列表来获得字母卡，每完成一个任务即可随机获得一个字母，用户集齐“TIGER”五个字母即可参与瓜分百万股票代金券，每个用户单日最多可获得20张字母卡（不包括好友赠予和魔法卡）。 用户在活动期间邀请累计7名好友完成注册并开户（注册时间和开户时间均在活动期间），即可获得一张魔法卡（每人仅可获得一张魔法卡）。魔法卡可用于兑换TIGER中的任意一个字母。如果用户的某一字母卡数量为0，则字母卡为灰色，用户可通过点击灰色的字母卡向好友索要卡片；如果用户的字母卡数量大于0，则字母卡为彩色，用户可通过点击彩色的字母卡向好友赠送卡片。当用户集齐TIGER之后将无法再索要卡片或者赠送卡片。  如何获得奖励？ 用户可在2021年7月1日至2021年7月2日期间进行开奖，所有集齐TIGER的客户可点击活动页面的“开奖”按钮，即可查看自己瓜分到的股票代金券奖励。在开奖时间段内未点击开奖的用户将无法获得奖励。 奖励发放： 股票代金券将在开奖后的1个工作日内发放至用户的奖励中心，用户需要在奖励发放后的20天内前往【Tiger Trade APP > 我的 > 活动奖励】领取，过期未领取的奖励将自动失效。 重要提示： 本次7周年活动涉及不同国家和地区，由于各地区的监管要求不同，不同地区的活动奖励会有所区别。欲知详情，请点击下方活动链接，登陆您的账号，并点击“活动规则“查看详情。","text":"老虎7周年给大家发福利了，集齐TIGER五个字母即有机会瓜分百万奖金，你准备好了吗？ 戳我即可参与活动 \u0001如何参与？ 用户可通过完成活动页面展示的当日任务列表来获得字母卡，每完成一个任务即可随机获得一个字母，用户集齐“TIGER”五个字母即可参与瓜分百万股票代金券，每个用户单日最多可获得20张字母卡（不包括好友赠予和魔法卡）。 用户在活动期间邀请累计7名好友完成注册并开户（注册时间和开户时间均在活动期间），即可获得一张魔法卡（每人仅可获得一张魔法卡）。魔法卡可用于兑换TIGER中的任意一个字母。\u0001如果用户的某一字母卡数量为0，则字母卡为灰色，用户可通过点击灰色的字母卡向好友索要卡片；如果用户的字母卡数量大于0，则字母卡为彩色，用户可通过点击彩色的字母卡向好友赠送卡片。当用户集齐TIGER之后将无法再索要卡片或者赠送卡片。 \u0001 \u0001如何获得奖励？ 用户可在2021年7月1日至2021年7月2日期间进行开奖，所有集齐TIGER的客户可点击活动页面的“开奖”按钮，即可查看自己瓜分到的股票代金券奖励。在开奖时间段内未点击开奖的用户将无法获得奖励。\u0001 奖励发放： 股票代金券将在开奖后的1个工作日内发放至用户的奖励中心，用户需要在奖励发放后的20天内前往【Tiger Trade APP > 我的 > 活动奖励】领取，过期未领取的奖励将自动失效。 重要提示： 本次7周年活动涉及不同国家和地区，由于各地区的监管要求不同，不同地区的活动奖励会有所区别。欲知详情，请点击下方活动链接，登陆您的账号，并点击“活动规则“查看详情。","images":[{"img":"https://static.tigerbbs.com/ab28db31a19b458d604a8bf02becddd3","width":"415","height":"125"},{"img":"https://static.tigerbbs.com/5227ebb594fe55b532c840acef147d7b","width":"415","height":"495"},{"img":"https://static.tigerbbs.com/92e88357b534f504b3088bc22f577a83","width":"415","height":"326"}],"top":1,"highlighted":2,"essential":1,"paper":2,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/114899451","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":8,"langContent":"CN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":322,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":123518556,"gmtCreate":1624429005975,"gmtModify":1634006232788,"author":{"id":"3584774162933077","authorId":"3584774162933077","name":"Babaluke","avatar":"https://static.tigerbbs.com/cf1bdc263bcb63f2412eb36286eaedda","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3584774162933077","authorIdStr":"3584774162933077"},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/123518556","repostId":"2145671770","repostType":2,"repost":{"id":"2145671770","kind":"highlight","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1624422686,"share":"https://www.laohu8.com/m/news/2145671770?lang=&edition=full","pubTime":"2021-06-23 12:31","market":"sh","language":"en","title":"UPDATE 1-Hong Kong police arrest Apple Daily columnist under security law","url":"https://stock-news.laohu8.com/highlight/detail?id=2145671770","media":"Reuters","summary":"(Adds details) HONG KONG, June 23 (Reuters) - Hong Kong police arrested on Wednesday a columnist f","content":"<html><body><p>(Adds details)</p><p> HONG KONG, June 23 (Reuters) - Hong Kong police arrested on Wednesday a columnist for pro-democracy tabloid Apple Daily on suspicion of conspiring to collude with a foreign country or foreign forces, in another hit to the besieged newspaper.</p><p> The latest arrest came after police froze assets of companies linked to the newspaper and arrested five executives last week, moves that are likely to force the newspaper to shut down this week. </p><p> Police have said dozens of Apple Daily pieces may have violated the security law, the first instance of authorities taking aim at media articles under the legislation.</p><p> Rights groups, media organisations and Western governments have criticised the government's actions and expressed concern over freedom of the press and other rights in the Chinese-ruled city.</p><p> Police, who typically do not disclose the names of those arrested, said they had arrested a 55-year-old man on the national security charges. A senior executive at Next Digital</p><p> , which publishes Apple Daily, said a lead writer for editorials and a reporter were arrested, without identifying them. It was unclear why the reporter was arrested.</p><p> A police representative said they had no immediate information on a second arrest.</p><p> Hong Kong leader Carrie Lam said on Tuesday that criticism of last week's raid and arrests at Apple Daily amounted to attempts to \"beautify\" acts that endangered national security.</p><p> Apple Daily has come under increasing pressure since its tycoon owner and staunch Beijing critic, Jimmy Lai, was arrested last year under the contentious legislation. Lai, whose assets have also been frozen under the security law, is already serving a prison sentence for taking part in unauthorised assemblies.</p><p> According to an internal staff memo seen by Reuters, the tabloid, which employs about 600 journalists, looks set to close for good by Saturday.</p><p> (Writing by Marius Zaharia; Editing by Himani Sarkar and Gerry Doyle)</p><p>((marius.zaharia@thomsonreuters.com; +852 2843 6358;))</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>UPDATE 1-Hong Kong police arrest Apple Daily columnist under security law</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nUPDATE 1-Hong Kong police arrest Apple Daily columnist under security law\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-06-23 12:31</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p>(Adds details)</p><p> HONG KONG, June 23 (Reuters) - Hong Kong police arrested on Wednesday a columnist for pro-democracy tabloid Apple Daily on suspicion of conspiring to collude with a foreign country or foreign forces, in another hit to the besieged newspaper.</p><p> The latest arrest came after police froze assets of companies linked to the newspaper and arrested five executives last week, moves that are likely to force the newspaper to shut down this week. </p><p> Police have said dozens of Apple Daily pieces may have violated the security law, the first instance of authorities taking aim at media articles under the legislation.</p><p> Rights groups, media organisations and Western governments have criticised the government's actions and expressed concern over freedom of the press and other rights in the Chinese-ruled city.</p><p> Police, who typically do not disclose the names of those arrested, said they had arrested a 55-year-old man on the national security charges. A senior executive at Next Digital</p><p> , which publishes Apple Daily, said a lead writer for editorials and a reporter were arrested, without identifying them. It was unclear why the reporter was arrested.</p><p> A police representative said they had no immediate information on a second arrest.</p><p> Hong Kong leader Carrie Lam said on Tuesday that criticism of last week's raid and arrests at Apple Daily amounted to attempts to \"beautify\" acts that endangered national security.</p><p> Apple Daily has come under increasing pressure since its tycoon owner and staunch Beijing critic, Jimmy Lai, was arrested last year under the contentious legislation. Lai, whose assets have also been frozen under the security law, is already serving a prison sentence for taking part in unauthorised assemblies.</p><p> According to an internal staff memo seen by Reuters, the tabloid, which employs about 600 journalists, looks set to close for good by Saturday.</p><p> (Writing by Marius Zaharia; Editing by Himani Sarkar and Gerry Doyle)</p><p>((marius.zaharia@thomsonreuters.com; +852 2843 6358;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"09086":"华夏纳指-U","AAPL":"苹果","03086":"华夏纳指"},"source_url":"http://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2145671770","content_text":"(Adds details) HONG KONG, June 23 (Reuters) - Hong Kong police arrested on Wednesday a columnist for pro-democracy tabloid Apple Daily on suspicion of conspiring to collude with a foreign country or foreign forces, in another hit to the besieged newspaper. The latest arrest came after police froze assets of companies linked to the newspaper and arrested five executives last week, moves that are likely to force the newspaper to shut down this week. Police have said dozens of Apple Daily pieces may have violated the security law, the first instance of authorities taking aim at media articles under the legislation. Rights groups, media organisations and Western governments have criticised the government's actions and expressed concern over freedom of the press and other rights in the Chinese-ruled city. Police, who typically do not disclose the names of those arrested, said they had arrested a 55-year-old man on the national security charges. A senior executive at Next Digital , which publishes Apple Daily, said a lead writer for editorials and a reporter were arrested, without identifying them. It was unclear why the reporter was arrested. A police representative said they had no immediate information on a second arrest. Hong Kong leader Carrie Lam said on Tuesday that criticism of last week's raid and arrests at Apple Daily amounted to attempts to \"beautify\" acts that endangered national security. Apple Daily has come under increasing pressure since its tycoon owner and staunch Beijing critic, Jimmy Lai, was arrested last year under the contentious legislation. Lai, whose assets have also been frozen under the security law, is already serving a prison sentence for taking part in unauthorised assemblies. According to an internal staff memo seen by Reuters, the tabloid, which employs about 600 journalists, looks set to close for good by Saturday. (Writing by Marius Zaharia; Editing by Himani Sarkar and Gerry Doyle)((marius.zaharia@thomsonreuters.com; +852 2843 6358;))","news_type":1},"isVote":1,"tweetType":1,"viewCount":485,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":123510136,"gmtCreate":1624428873625,"gmtModify":1634006234187,"author":{"id":"3584774162933077","authorId":"3584774162933077","name":"Babaluke","avatar":"https://static.tigerbbs.com/cf1bdc263bcb63f2412eb36286eaedda","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3584774162933077","authorIdStr":"3584774162933077"},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/123510136","repostId":"1123710128","repostType":4,"repost":{"id":"1123710128","kind":"news","pubTimestamp":1624406277,"share":"https://www.laohu8.com/m/news/1123710128?lang=&edition=full","pubTime":"2021-06-23 07:57","market":"us","language":"en","title":"EVs Seen Reaching Sales Supremacy by 2033, Faster Than Expected","url":"https://stock-news.laohu8.com/highlight/detail?id=1123710128","media":"Bloomberg","summary":"(Bloomberg) -- Global electric vehicle supremacy will arrive by 2033 -- five years earlier than prev","content":"<p>(Bloomberg) -- Global electric vehicle supremacy will arrive by 2033 -- five years earlier than previously expected -- as tougher regulations and rising interest drive demand for zero-emission transportation, according to a new study.</p>\n<p>Consultant Ernst & Young LLP now sees EV sales outpacing fossil fuel-burners in 12 years in Europe, China and the U.S. -- the world’s largest auto markets. And by 2045, non-EV sales are seen plummeting to less than 1% of the global car market, EY forecast using an AI-powered prediction tool.</p>\n<p>Strict government mandates to combat climate change are driving demand in Europe and China, where automakers and consumers face rising financial penalties for selling and buying traditional gasoline and diesel-fueled cars. EY sees Europe leading the charge to electric, with zero-emission models outselling all other propulsion systems by 2028. That tipping point will arrive in China in 2033 and in the U.S. in 2036, EY predicts.</p>\n<p>The U.S. lags the world’s other leading markets because fuel-economy regulations were eased during President Donald Trump’s administration. Since taking office in January, President Joe Biden has rejoined the Paris Climate Accord and proposed spending $174 billion to accelerate the shift to EVs, including installing a half-million charging stations across the country.</p>\n<p>“The regulatory environment from the Biden administration we view as a big contributor, because he has ambitious targets,” Randy Miller, EY’s global advanced manufacturing and mobility leader, said in an interview. “That impact in the Americas will have a supercharging effect.”</p>\n<p>There also is a growing consumer appetite for EVs, from Tesla Inc.’s hot-selling Model 3 to new electric models coming from legacy automakers, such as General Motors Co.’s battery-powered Hummer truck and Ford Motor Co.’s F-150 Lightning pickup. Investments in battery powered models now top $230 billion from the world’s automakers, according to consultant AlixPartners.</p>\n<p>‘More Appealing’</p>\n<p>“Many more models that are much more appealing are coming out,” Miller said. “You factor that with the incentives, and those are the raw ingredients that are driving this more optimistic view.”</p>\n<p>The EY study also sees the millennial generation, now in their late 20s and 30s, as helping to propel EV adoption. Those consumers, driven by a coronavirus-influenced rejection of ride-sharing and public transportation, are embracing car ownership. And 30% of them want to drive an EV, Miller said.</p>\n<p>“The view from the millennials that we’re seeing is clearly more inclination to want to buy EVs,” Miller said.</p>\n<p>Additionally, the combination of government purchase incentives for EVs and proposed bans on internal combustion engines in cities and states are accelerating the adoption of battery-powered vehicles.</p>\n<p>Europe is forecast to lead in EV sales volumes until 2031, when China will become the world’s top market for electric vehicles.</p>\n<p>Vehicles powered by gasoline and diesel are still predicted to make up around two-thirds of all light vehicle registrations in 2025, but that will mark a 12 percentage-point decrease from five years earlier. By 2030, EY predicts that non-EV cars will account for less than half of overall light vehicle registrations.</p>","source":"lsy1612507957220","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>EVs Seen Reaching Sales Supremacy by 2033, Faster Than Expected</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEVs Seen Reaching Sales Supremacy by 2033, Faster Than Expected\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-23 07:57 GMT+8 <a href=https://finance.yahoo.com/news/evs-seen-reaching-sales-supremacy-230100585.html><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>(Bloomberg) -- Global electric vehicle supremacy will arrive by 2033 -- five years earlier than previously expected -- as tougher regulations and rising interest drive demand for zero-emission ...</p>\n\n<a href=\"https://finance.yahoo.com/news/evs-seen-reaching-sales-supremacy-230100585.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NIO":"蔚来","TSLA":"特斯拉"},"source_url":"https://finance.yahoo.com/news/evs-seen-reaching-sales-supremacy-230100585.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1123710128","content_text":"(Bloomberg) -- Global electric vehicle supremacy will arrive by 2033 -- five years earlier than previously expected -- as tougher regulations and rising interest drive demand for zero-emission transportation, according to a new study.\nConsultant Ernst & Young LLP now sees EV sales outpacing fossil fuel-burners in 12 years in Europe, China and the U.S. -- the world’s largest auto markets. And by 2045, non-EV sales are seen plummeting to less than 1% of the global car market, EY forecast using an AI-powered prediction tool.\nStrict government mandates to combat climate change are driving demand in Europe and China, where automakers and consumers face rising financial penalties for selling and buying traditional gasoline and diesel-fueled cars. EY sees Europe leading the charge to electric, with zero-emission models outselling all other propulsion systems by 2028. That tipping point will arrive in China in 2033 and in the U.S. in 2036, EY predicts.\nThe U.S. lags the world’s other leading markets because fuel-economy regulations were eased during President Donald Trump’s administration. Since taking office in January, President Joe Biden has rejoined the Paris Climate Accord and proposed spending $174 billion to accelerate the shift to EVs, including installing a half-million charging stations across the country.\n“The regulatory environment from the Biden administration we view as a big contributor, because he has ambitious targets,” Randy Miller, EY’s global advanced manufacturing and mobility leader, said in an interview. “That impact in the Americas will have a supercharging effect.”\nThere also is a growing consumer appetite for EVs, from Tesla Inc.’s hot-selling Model 3 to new electric models coming from legacy automakers, such as General Motors Co.’s battery-powered Hummer truck and Ford Motor Co.’s F-150 Lightning pickup. Investments in battery powered models now top $230 billion from the world’s automakers, according to consultant AlixPartners.\n‘More Appealing’\n“Many more models that are much more appealing are coming out,” Miller said. “You factor that with the incentives, and those are the raw ingredients that are driving this more optimistic view.”\nThe EY study also sees the millennial generation, now in their late 20s and 30s, as helping to propel EV adoption. Those consumers, driven by a coronavirus-influenced rejection of ride-sharing and public transportation, are embracing car ownership. And 30% of them want to drive an EV, Miller said.\n“The view from the millennials that we’re seeing is clearly more inclination to want to buy EVs,” Miller said.\nAdditionally, the combination of government purchase incentives for EVs and proposed bans on internal combustion engines in cities and states are accelerating the adoption of battery-powered vehicles.\nEurope is forecast to lead in EV sales volumes until 2031, when China will become the world’s top market for electric vehicles.\nVehicles powered by gasoline and diesel are still predicted to make up around two-thirds of all light vehicle registrations in 2025, but that will mark a 12 percentage-point decrease from five years earlier. By 2030, EY predicts that non-EV cars will account for less than half of overall light vehicle registrations.","news_type":1},"isVote":1,"tweetType":1,"viewCount":431,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":123597682,"gmtCreate":1624428375546,"gmtModify":1634006238087,"author":{"id":"3584774162933077","authorId":"3584774162933077","name":"Babaluke","avatar":"https://static.tigerbbs.com/cf1bdc263bcb63f2412eb36286eaedda","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3584774162933077","authorIdStr":"3584774162933077"},"themes":[],"htmlText":"What","listText":"What","text":"What","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/123597682","repostId":"1123710128","repostType":4,"isVote":1,"tweetType":1,"viewCount":313,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":123597355,"gmtCreate":1624428362077,"gmtModify":1634006238208,"author":{"id":"3584774162933077","authorId":"3584774162933077","name":"Babaluke","avatar":"https://static.tigerbbs.com/cf1bdc263bcb63f2412eb36286eaedda","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3584774162933077","authorIdStr":"3584774162933077"},"themes":[],"htmlText":"Yums","listText":"Yums","text":"Yums","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/123597355","repostId":"1126010678","repostType":4,"repost":{"id":"1126010678","kind":"news","pubTimestamp":1624412603,"share":"https://www.laohu8.com/m/news/1126010678?lang=&edition=full","pubTime":"2021-06-23 09:43","market":"us","language":"en","title":"Krispy Kreme Seeks $640 Million in IPO as Sales Move Online","url":"https://stock-news.laohu8.com/highlight/detail?id=1126010678","media":"Bloomberg","summary":"(Bloomberg) -- Krispy Kreme Inc., the doughnut chain owned by JAB Holdings BV, is seeking to raise a","content":"<p>(Bloomberg) -- Krispy Kreme Inc., the doughnut chain owned by JAB Holdings BV, is seeking to raise as much as $640 million in an initial public offering.</p>\n<p>The company said in a filing Tuesday that it plans to sell almost 27 million shares for $21 to $24 apiece. At the top end of the range, Krispy Kreme would have a market value of $3.86 billion based on the outstanding shares listed in the filing with the U.S. Securities and Exchange Commission.</p>\n<p>Amid photos of doughnuts dripping with sugary glaze and dotted with sprinkles, the company declares in the filing that its purpose is “to touch and enhance lives through the joy of Krispy Kreme.”</p>\n<p>Since its acquisition by Luxembourg-based conglomerate JAB in 2016, Krispy Kreme has expanded its online presence. Its e-commerce business now accounts for close to a fifth of sales in the U.S., fueled by its Insomnia Cookies delivery concept.</p>\n<p>Net revenue for the Charlotte, North Carolina-based chain rose 23% to $322 million in the quarter ended April 4, according to the filing. Its net loss for the quarter shrunk from $11 million in 2020 to $378,000 this year.</p>\n<p>Krispy Kreme plans to use proceeds from the IPO to pay down debt and buy back shares from certain executives, as well as for general corporate purposes, according to the filing. JAB will continue to own almost 78% of the company’s shares after the IPO.</p>\n<p>The offering is being led by JPMorgan Chase & Co., Morgan Stanley, Bank of America Corp. and Citigroup Inc. The company plans to list on the Nasdaq Global Select Market under the symbol DNUT.</p>","source":"lsy1612507957220","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Krispy Kreme Seeks $640 Million in IPO as Sales Move Online</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nKrispy Kreme Seeks $640 Million in IPO as Sales Move Online\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-23 09:43 GMT+8 <a href=https://finance.yahoo.com/news/krispy-kreme-sets-price-range-154753866.html><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>(Bloomberg) -- Krispy Kreme Inc., the doughnut chain owned by JAB Holdings BV, is seeking to raise as much as $640 million in an initial public offering.\nThe company said in a filing Tuesday that it ...</p>\n\n<a href=\"https://finance.yahoo.com/news/krispy-kreme-sets-price-range-154753866.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"DNUT":"Krispy Kreme, Inc."},"source_url":"https://finance.yahoo.com/news/krispy-kreme-sets-price-range-154753866.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1126010678","content_text":"(Bloomberg) -- Krispy Kreme Inc., the doughnut chain owned by JAB Holdings BV, is seeking to raise as much as $640 million in an initial public offering.\nThe company said in a filing Tuesday that it plans to sell almost 27 million shares for $21 to $24 apiece. At the top end of the range, Krispy Kreme would have a market value of $3.86 billion based on the outstanding shares listed in the filing with the U.S. Securities and Exchange Commission.\nAmid photos of doughnuts dripping with sugary glaze and dotted with sprinkles, the company declares in the filing that its purpose is “to touch and enhance lives through the joy of Krispy Kreme.”\nSince its acquisition by Luxembourg-based conglomerate JAB in 2016, Krispy Kreme has expanded its online presence. Its e-commerce business now accounts for close to a fifth of sales in the U.S., fueled by its Insomnia Cookies delivery concept.\nNet revenue for the Charlotte, North Carolina-based chain rose 23% to $322 million in the quarter ended April 4, according to the filing. Its net loss for the quarter shrunk from $11 million in 2020 to $378,000 this year.\nKrispy Kreme plans to use proceeds from the IPO to pay down debt and buy back shares from certain executives, as well as for general corporate purposes, according to the filing. JAB will continue to own almost 78% of the company’s shares after the IPO.\nThe offering is being led by JPMorgan Chase & Co., Morgan Stanley, Bank of America Corp. and Citigroup Inc. The company plans to list on the Nasdaq Global Select Market under the symbol DNUT.","news_type":1},"isVote":1,"tweetType":1,"viewCount":353,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":123594843,"gmtCreate":1624428337982,"gmtModify":1634006238572,"author":{"id":"3584774162933077","authorId":"3584774162933077","name":"Babaluke","avatar":"https://static.tigerbbs.com/cf1bdc263bcb63f2412eb36286eaedda","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3584774162933077","authorIdStr":"3584774162933077"},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/123594843","repostId":"2145057786","repostType":4,"isVote":1,"tweetType":1,"viewCount":296,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":123595713,"gmtCreate":1624428311132,"gmtModify":1634006238814,"author":{"id":"3584774162933077","authorId":"3584774162933077","name":"Babaluke","avatar":"https://static.tigerbbs.com/cf1bdc263bcb63f2412eb36286eaedda","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3584774162933077","authorIdStr":"3584774162933077"},"themes":[],"htmlText":"Cool","listText":"Cool","text":"Cool","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/123595713","repostId":"2145066250","repostType":4,"isVote":1,"tweetType":1,"viewCount":323,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":123592750,"gmtCreate":1624428287070,"gmtModify":1634006239664,"author":{"id":"3584774162933077","authorId":"3584774162933077","name":"Babaluke","avatar":"https://static.tigerbbs.com/cf1bdc263bcb63f2412eb36286eaedda","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3584774162933077","authorIdStr":"3584774162933077"},"themes":[],"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/123592750","repostId":"1192380860","repostType":4,"repost":{"id":"1192380860","kind":"news","pubTimestamp":1624418912,"share":"https://www.laohu8.com/m/news/1192380860?lang=&edition=full","pubTime":"2021-06-23 11:28","market":"us","language":"en","title":"GSAT Stock: Why One Analyst Sees 150%+ Upside for Globalstar","url":"https://stock-news.laohu8.com/highlight/detail?id=1192380860","media":"investorplace","summary":"Globalstar(NYSEAMERICAN:GSAT) shares are rising higher on Monday after an analyst initiated coverage","content":"<p><b>Globalstar</b>(NYSEAMERICAN:<b><u>GSAT</u></b>) shares are rising higher on Monday after an analyst initiated coverage of the stock with an incredibly bullish stance.</p>\n<p>B. Riley analyst Mike Crawford is behind the positive movement for GSAT stock today. He started off coverage of the stock witha buy rating. That has him opposite of the only other analyst covering the stockwith their sell rating. This means the consensus rating for the stock is hold.</p>\n<p>In addition to that bullish buy rating, Crawford also includes a price target of $3.25 per share for GSAT stock. That is well above the consensus price target of 55 cents per share for the stock. It’s also a massive 152% upside for the stock over its closing price of $1.29 per share when markets closed on Friday.</p>\n<p>So what has this B. Riley analyst taking such a bullish stance on GSAT stock. It all has to do with the company’s future potential.</p>\n<p>According to Crawford, Globalstar is finally getting to a point where it will start reporting returns. He believes that this makes it a great time to jump into the stock before the market figures this out, reports<i>TheFly.com</i>.</p>\n<p>Investors seem to agree as GSAT is seeing heavy trading today. As of this writing, more than 114 million shares of the stock have changed hands. That’s a massive jump over its daily average trading volume of about 19.3 million shares.</p>\n<p>GSAT stock was up 19.8% as of Monday afternoon and is up 352.9% since the start of the year.</p>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>GSAT Stock: Why One Analyst Sees 150%+ Upside for Globalstar</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGSAT Stock: Why One Analyst Sees 150%+ Upside for Globalstar\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-23 11:28 GMT+8 <a href=https://investorplace.com/2021/06/gsat-stock-why-one-analyst-sees-150-upside-for-globalstar/><strong>investorplace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Globalstar(NYSEAMERICAN:GSAT) shares are rising higher on Monday after an analyst initiated coverage of the stock with an incredibly bullish stance.\nB. Riley analyst Mike Crawford is behind the ...</p>\n\n<a href=\"https://investorplace.com/2021/06/gsat-stock-why-one-analyst-sees-150-upside-for-globalstar/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"GSAT":"全球星"},"source_url":"https://investorplace.com/2021/06/gsat-stock-why-one-analyst-sees-150-upside-for-globalstar/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1192380860","content_text":"Globalstar(NYSEAMERICAN:GSAT) shares are rising higher on Monday after an analyst initiated coverage of the stock with an incredibly bullish stance.\nB. Riley analyst Mike Crawford is behind the positive movement for GSAT stock today. He started off coverage of the stock witha buy rating. That has him opposite of the only other analyst covering the stockwith their sell rating. This means the consensus rating for the stock is hold.\nIn addition to that bullish buy rating, Crawford also includes a price target of $3.25 per share for GSAT stock. That is well above the consensus price target of 55 cents per share for the stock. It’s also a massive 152% upside for the stock over its closing price of $1.29 per share when markets closed on Friday.\nSo what has this B. Riley analyst taking such a bullish stance on GSAT stock. It all has to do with the company’s future potential.\nAccording to Crawford, Globalstar is finally getting to a point where it will start reporting returns. He believes that this makes it a great time to jump into the stock before the market figures this out, reportsTheFly.com.\nInvestors seem to agree as GSAT is seeing heavy trading today. As of this writing, more than 114 million shares of the stock have changed hands. That’s a massive jump over its daily average trading volume of about 19.3 million shares.\nGSAT stock was up 19.8% as of Monday afternoon and is up 352.9% since the start of the year.","news_type":1},"isVote":1,"tweetType":1,"viewCount":433,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":123592828,"gmtCreate":1624428233064,"gmtModify":1634006240151,"author":{"id":"3584774162933077","authorId":"3584774162933077","name":"Babaluke","avatar":"https://static.tigerbbs.com/cf1bdc263bcb63f2412eb36286eaedda","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3584774162933077","authorIdStr":"3584774162933077"},"themes":[],"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/123592828","repostId":"1174011543","repostType":4,"repost":{"id":"1174011543","kind":"news","pubTimestamp":1624425845,"share":"https://www.laohu8.com/m/news/1174011543?lang=&edition=full","pubTime":"2021-06-23 13:24","market":"us","language":"en","title":"FDA Approved Biogen Alzheimer’s Drug Despite Some Staff Concerns","url":"https://stock-news.laohu8.com/highlight/detail?id=1174011543","media":"WSJ","summary":"The U.S. Food and Drug Administrationapproved the first new Alzheimer’s drug in decadesover the obje","content":"<p>The U.S. Food and Drug Administrationapproved the first new Alzheimer’s drug in decadesover the objection of agency statisticians who said there was insufficient evidence to support approval, according to newly released internal memos.</p>\n<p>In the internal memos released Tuesday, FDA officials discussed whether to approve the drug fromBiogenInc.BIIB-1.71%over objections from the agency’s drug statistics office, which said that clinical trial data fell short of the proof typically required to put a new product on the market.</p>\n<p>Ultimately, top officials decided that the evidence indicating that the drug worked, while inconclusive, was strong enough to allow doctors and patients to decide for themselves whether to take it, according to the memos.</p>\n<p>“FDA, then, is faced with a situation where the available evidence on the clinical endpoints is short of what we would require for standard approval of aducanumab,” wrote Peter Stein, director of the FDA’s office of new drugs, in a memo detailing his support for approval. “At the same time, patients with [Alzheimer’s] have a serious, progressive, ultimately fatal disease and are desperate for treatments.”</p>\n<p>The FDA made public its internal deliberations as it faces criticism from some doctors and scientists over the June 7 approval of the drug, called Aduhelm.</p>\n<p>The critics say the FDA ignored the scientific standards it typically holds drugmakers to and could prompt the federal government to spend billions of dollars on a drug that may not work.</p>\n<p>“While I fully support the Center’s recent decision to approve the therapy, I acknowledge that there are different opinions about this decision, including within FDA, and there likely will continue to be questions around our process for review and the data we considered to support the approval,” said FDA Acting Commissioner Janet Woodcock. “In the end, an experienced group of medical reviewers at FDA concluded that there was sufficient evidence to approve the Alzheimer’s therapy via the accelerated approval pathway.”</p>\n<p>Supporters say the FDA decision provides a lifeline to patients who have lacked any medicine promising to slow the progression of Alzheimer’s, and that the decision couldspur the development of more, better medicines.</p>\n<p>The agency usually releases approval documents after a decision, though not typically as quickly as it did this time. The 83 pages of memos appear to be a portion of the FDA’s deliberations, largely reflecting the exchanges of top officials.</p>\n<p>Tristan Massie, a biostatistics reviewer for the FDA, “does not agree that the totality of the data provides sufficient evidence to support the efficacy of aducanumab in Alzheimer’s disease and does not recommend approval,” one of the internal documents shows.</p>\n<p>Patrizia Cavazzoni, the FDA’s top-ranking drug-evaluation official, wrote in another memo that the agency’s drug biostatistics office “provided documentation for its recommendation that substantial evidence of effectiveness had not been provided in the application.”</p>\n<p>That office’s full dissenting analysis wasn’t included in the materials made available Tuesday, but portions of it were.</p>\n<p>Despite the objections, Dr. Cavazzoni wrote that Biogen had met the requirements for an “accelerated approval,” a type of regulatory clearance that allows a drug to be marketed even when there remains uncertainty about its clinical benefit if it fills an unmet need for a serious disease and has effects against a biological sign of the disease.</p>\n<p>Dr. Cavazzoni wrote that Aduhelm met that standard because of its effect of reducing a sticky substance called amyloid which “is reasonably likely to predict clinical benefit.”</p>\n<p>Some doctors and scientists saytargeting the amyloid plaqueshasn’t been proven to slow Alzheimer’s. Some members of a panel of advisers that recommended the FDA reject the drug haveresigned from the committee, citing the agency’s approval.</p>\n<p>Biogen listed the price of Aduhelm at $56,000 a year, and patients and Medicare could also face testing charges.</p>\n<p>About six million Americans suffer from Alzheimer’s, a progressive condition that robs people of their memories and cognitive abilities. Biogen has said that as many as two million of them may benefit from the medicine.</p>\n<p>The FDA approval sent Biogen’s stock soaring. The company has said it expects only minimal revenue from the drug this year, in part because of the logistical challenges in administering the medicine, but that sales would begin to increase next year.</p>\n<p>Analysts estimate sales of $946.3 million in 2022, according to FactSet. Sales are seen growing to $5.2 billion in 2026.</p>\n<p>The memos show FDA officials attempting to balance the subpar study data for Aduhelm with the desire of Alzheimer’s patients and their families to try any new treatment that might help.</p>\n<p>“There remains residual uncertainty regarding clinical benefit,” Dr. Stein wrote. But if the FDA were to wait for the company to finish another clinical study, “any approval would occur after a multiple year delay” and patients “could suffer irreversible loss of brain neurons and cognitive function and memory,” he wrote.</p>\n<p>The FDA said it plans to release more documents regarding its decision making as early as next week.</p>\n<p>The FDA’s approval was based primarily on two large Phase 3 clinical trials launched by Biogen to prove its drug helped slow the cognitive decline of people with early-stage Alzheimer’s.</p>\n<p>In March 2019, the companyhalted the studies earlyafter an independent monitoring board concluded the drug was unlikely to help patients.</p>\n<p>Seven months later, however,the company made a surprising reversaland said it was now planning to seek FDA approval after conducting additional analyses of trial data that came in after the studies were halted. The company said its analyses found the drug was successful in one study but failed in the second.</p>\n<p>The FDA memos provide some new details on Biogen’s about-face. In June 2019, the company met with FDA officials and both sides agreed the studies shouldn’t have been stopped, according to a “summary memorandum” document.</p>\n<p>At the meeting, FDA officials recommended that Biogen analyze the studies further to understand if it was still possible to draw conclusions from the data, despite the halt of the trials and conflicting results.</p>\n<p>Several months later, in October 2019, the agency and company met again and agreed that the studies could still be used to evaluate the drug’s effectiveness, according to the memo.</p>\n<p>The following day, on Oct. 22, Biogen announcedit would seek approval for the medicine, sending up its share price and adding billions of dollars to its market value.</p>\n<p>The company had been quietly re-examining the data for months, but didn’t have the confidence to move forward until the latest meeting with FDA officials, Biogen Chief Executive Michel Vounatsos said in an interview at the time.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>FDA Approved Biogen Alzheimer’s Drug Despite Some Staff Concerns</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFDA Approved Biogen Alzheimer’s Drug Despite Some Staff Concerns\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-23 13:24 GMT+8 <a href=https://www.wsj.com/articles/fda-approved-biogen-alzheimers-drug-despite-some-staff-concerns-11624393800?mod=hp_lead_pos2><strong>WSJ</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The U.S. Food and Drug Administrationapproved the first new Alzheimer’s drug in decadesover the objection of agency statisticians who said there was insufficient evidence to support approval, ...</p>\n\n<a href=\"https://www.wsj.com/articles/fda-approved-biogen-alzheimers-drug-despite-some-staff-concerns-11624393800?mod=hp_lead_pos2\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BIIB":"渤健公司"},"source_url":"https://www.wsj.com/articles/fda-approved-biogen-alzheimers-drug-despite-some-staff-concerns-11624393800?mod=hp_lead_pos2","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1174011543","content_text":"The U.S. Food and Drug Administrationapproved the first new Alzheimer’s drug in decadesover the objection of agency statisticians who said there was insufficient evidence to support approval, according to newly released internal memos.\nIn the internal memos released Tuesday, FDA officials discussed whether to approve the drug fromBiogenInc.BIIB-1.71%over objections from the agency’s drug statistics office, which said that clinical trial data fell short of the proof typically required to put a new product on the market.\nUltimately, top officials decided that the evidence indicating that the drug worked, while inconclusive, was strong enough to allow doctors and patients to decide for themselves whether to take it, according to the memos.\n“FDA, then, is faced with a situation where the available evidence on the clinical endpoints is short of what we would require for standard approval of aducanumab,” wrote Peter Stein, director of the FDA’s office of new drugs, in a memo detailing his support for approval. “At the same time, patients with [Alzheimer’s] have a serious, progressive, ultimately fatal disease and are desperate for treatments.”\nThe FDA made public its internal deliberations as it faces criticism from some doctors and scientists over the June 7 approval of the drug, called Aduhelm.\nThe critics say the FDA ignored the scientific standards it typically holds drugmakers to and could prompt the federal government to spend billions of dollars on a drug that may not work.\n“While I fully support the Center’s recent decision to approve the therapy, I acknowledge that there are different opinions about this decision, including within FDA, and there likely will continue to be questions around our process for review and the data we considered to support the approval,” said FDA Acting Commissioner Janet Woodcock. “In the end, an experienced group of medical reviewers at FDA concluded that there was sufficient evidence to approve the Alzheimer’s therapy via the accelerated approval pathway.”\nSupporters say the FDA decision provides a lifeline to patients who have lacked any medicine promising to slow the progression of Alzheimer’s, and that the decision couldspur the development of more, better medicines.\nThe agency usually releases approval documents after a decision, though not typically as quickly as it did this time. The 83 pages of memos appear to be a portion of the FDA’s deliberations, largely reflecting the exchanges of top officials.\nTristan Massie, a biostatistics reviewer for the FDA, “does not agree that the totality of the data provides sufficient evidence to support the efficacy of aducanumab in Alzheimer’s disease and does not recommend approval,” one of the internal documents shows.\nPatrizia Cavazzoni, the FDA’s top-ranking drug-evaluation official, wrote in another memo that the agency’s drug biostatistics office “provided documentation for its recommendation that substantial evidence of effectiveness had not been provided in the application.”\nThat office’s full dissenting analysis wasn’t included in the materials made available Tuesday, but portions of it were.\nDespite the objections, Dr. Cavazzoni wrote that Biogen had met the requirements for an “accelerated approval,” a type of regulatory clearance that allows a drug to be marketed even when there remains uncertainty about its clinical benefit if it fills an unmet need for a serious disease and has effects against a biological sign of the disease.\nDr. Cavazzoni wrote that Aduhelm met that standard because of its effect of reducing a sticky substance called amyloid which “is reasonably likely to predict clinical benefit.”\nSome doctors and scientists saytargeting the amyloid plaqueshasn’t been proven to slow Alzheimer’s. Some members of a panel of advisers that recommended the FDA reject the drug haveresigned from the committee, citing the agency’s approval.\nBiogen listed the price of Aduhelm at $56,000 a year, and patients and Medicare could also face testing charges.\nAbout six million Americans suffer from Alzheimer’s, a progressive condition that robs people of their memories and cognitive abilities. Biogen has said that as many as two million of them may benefit from the medicine.\nThe FDA approval sent Biogen’s stock soaring. The company has said it expects only minimal revenue from the drug this year, in part because of the logistical challenges in administering the medicine, but that sales would begin to increase next year.\nAnalysts estimate sales of $946.3 million in 2022, according to FactSet. Sales are seen growing to $5.2 billion in 2026.\nThe memos show FDA officials attempting to balance the subpar study data for Aduhelm with the desire of Alzheimer’s patients and their families to try any new treatment that might help.\n“There remains residual uncertainty regarding clinical benefit,” Dr. Stein wrote. But if the FDA were to wait for the company to finish another clinical study, “any approval would occur after a multiple year delay” and patients “could suffer irreversible loss of brain neurons and cognitive function and memory,” he wrote.\nThe FDA said it plans to release more documents regarding its decision making as early as next week.\nThe FDA’s approval was based primarily on two large Phase 3 clinical trials launched by Biogen to prove its drug helped slow the cognitive decline of people with early-stage Alzheimer’s.\nIn March 2019, the companyhalted the studies earlyafter an independent monitoring board concluded the drug was unlikely to help patients.\nSeven months later, however,the company made a surprising reversaland said it was now planning to seek FDA approval after conducting additional analyses of trial data that came in after the studies were halted. The company said its analyses found the drug was successful in one study but failed in the second.\nThe FDA memos provide some new details on Biogen’s about-face. In June 2019, the company met with FDA officials and both sides agreed the studies shouldn’t have been stopped, according to a “summary memorandum” document.\nAt the meeting, FDA officials recommended that Biogen analyze the studies further to understand if it was still possible to draw conclusions from the data, despite the halt of the trials and conflicting results.\nSeveral months later, in October 2019, the agency and company met again and agreed that the studies could still be used to evaluate the drug’s effectiveness, according to the memo.\nThe following day, on Oct. 22, Biogen announcedit would seek approval for the medicine, sending up its share price and adding billions of dollars to its market value.\nThe company had been quietly re-examining the data for months, but didn’t have the confidence to move forward until the latest meeting with FDA officials, Biogen Chief Executive Michel Vounatsos said in an interview at the time.","news_type":1},"isVote":1,"tweetType":1,"viewCount":389,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"lives":[]}
